WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2012-- Avedro, Inc., a global ophthalmic medical device and pharmaceutical company, has announced that it has expanded its portfolio of proprietary riboflavin formulations for corneal collagen cross-linking. When used in conjunction with Avedro's KXL(TM) System, these new formulations further reduce the time required to perform cross-linking and in some applications improve cross-linking utility.
"Avedro's KXL System for accelerated cross-linking is available in over 50 countries, and has been used in combination with our VibeX riboflavin to treat tens of thousands of eyes world-wide," said David Muller, PhD, President and CEO of Avedro. "Our research team has done an excellent job expanding the available riboflavins to meet the specific needs of our user physicians and their patients." Avedro's family of riboflavin products is commercially available in countries recognizing the CE Mark, and includes: -- VibeX(TM)(original formulation) - For traditional, epithelium-off cross-linking -- VibeX Rapid(TM) - For faster diffusion -- VibeX Xtra(TM) - For use during LASIK or PRK surgery, formulated for direct application to the stromal bed to restore corneal biomechanical strength -- ParaCel(TM)- For trans-epithelial cross-linking, offering the fastest penetrating formula available "ParaCel provides for an easier, faster and more comfortable cross-linking procedure when treating my keratoconic and ectasia patients," said Roberto Pinelli, MD, Director of the Istituto Laser Microchirurgia Oculare (ILMO). Dr. Pinelli further stated, "When using ParaCel in combination with Avedro's KXL System, I am able to treat my keratoconic patients in a much shorter time, without the post-operative discomfort associated with removal of the epithelium." ParaCel's formulation is based on the research of Dr. Pinelli and his associated patent, which has been assigned to Avedro.
Avedro is currently the only medical device company sponsoring on-going Phase III cross-linking clinical trials in the US.
About Avedro, Inc.Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal collagen cross-linking. The Company's advanced cross-linking technology makes the treatment of keratoconus and post-LASIK ectasia safer, faster and more comfortable, while also making possible an entirely new cross-linking procedure, Lasik Xtra(TM), which restores the cornea's biomechanical integrity following the creation of the LASIK flap and/or excimer laser ablation during LASIK or PRK. Outside the US, Avedro has obtained CE Mark for its KXL System for performing accelerated corneal cross-linking and for its family of riboflavin products. Avedro products are not for sale in the US.
CONTACT: Avedro, Inc Kristen Gleason, 781-768-3400 email@example.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES OPTICAL PHARMACEUTICAL SOURCE: Avedro, Inc.
Copyright Business Wire 2012 PUB: 06/12/2012 12:01 AM/DISC: 06/12/2012 12:01 AM http://www.businesswire.com/news/home/20120611006668/